HTG Molecular Diagnostics Receives a Buy from Canaccord Genuity

Canaccord Genuity analyst Mark Massaro reiterated a Buy rating on HTG Molecular Diagnostics (NASDAQ: HTGM) yesterday and set a price target of $5.50. The company’s shares opened today at $3.94.

According to, Massaro is a 5-star analyst with an average return of 12.2% and a 60.1% success rate. Massaro covers the Healthcare sector, focusing on stocks such as Meridian Bioscience Inc, Quest Diagnostics Inc, and Orasure Technologies.

HTG Molecular Diagnostics has an analyst consensus of Moderate Buy, with a price target consensus of $5.50.

Based on HTG Molecular Diagnostics’ latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $1.37 million and GAAP net loss of $5.82 million. In comparison, last year the company earned revenue of $865.2K and had a GAAP net loss of $7.03 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

HTG Molecular Diagnostics, Inc. provides molecular technology solutions. It offers products for miRNA, and mRNA measurement for translational research/medicine and molecular diagnostics. Its qNPA molecular technology platform detects changes in gene expression levels; especially from formalin-fixed, paraffin-embedded tissue and other biological sample types. It also offers pharma and diagnostics services. The company was founded by Bruce E. Seligmann in October 1997 and is headquartered in Tucson, AZ.

Leave a Reply

Your email address will not be published. Required fields are marked *